Researchers Unveil Novel Cancer Biomarkers to Support Early Cancer Detection
The global cancer diagnostics market was valued at USD 134.16 billion in 2018. Rising prevalence of cancer and technological advancement in molecular diagnostics together drive the cancer diagnostics market. Growing prevalence of cancer instances likely to benefit large scale adoption of advanced cancer diagnostics concludes Adroit Market Research in its recent research compilation pertaining to cancer diagnostics.
Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/95
Leading researchers at Lund University of Sweden have affirmed emergence of new cancer biomarkers that enables cost efficient and quick identification of cancer biomarkers. The development of novel cancer diagnostics is scaling heights with constant rise in cancer incidences, rising fatality and advances in R&D expeditions to enable quick and effective cancer biomarkers. The role of predictive diagnostics is massive in adequate cancer diagnostics expeditions. According to WHO assessment, early diagnostics of cancer prevalence improves chances of complete cure.
Novel Milestones in Cancer Diagnostics also Affirm the Competence of Discarded Cancerous Tumor in Progressive Studies
These advances are estimated to improve cure potential and further expedite growth in cancer diagnostics market. Researchers at Lund University in collaboration with research Immunovia AB are participating in the development of new technology with improved antibodies and next generation sequencing technologies that collectively improve cancer diagnostics further. Advances in cancer diagnostics is also characterized by the detailed study of cancerous tumor tissues which often gets eliminated post cancer surgeries.
Read complete report at: https://www.adroitmarketresearch.com/industry-reports/cancer-diagnostics-market
Blood-based Liquid Biopsy Goes Mainstream as Non-Invasive Cancer Diagnostics Pick Heights
With noninvasive diagnostic methods witnessing magnificent adoption, blood based liquid biopsy methods are becoming mainstream to support early cancer detection ventures. As precision medicine or customized therapeutics are advancing relentlessly, targeting cancer therapeutics, liquid biopsy is emerging as the most effective cancer diagnostic medium in recent years.
The key players actively engaged in the production of cancer diagnostics are Agilent Technologies, Inc., Becton Dickinson & Company, bioMeriux SA, Danaher Corporation, GE Healthcare, Hologic, Inc., Illumina, Inc., Philips Healthcare, Qiagen, Siemens Healthineers and Thermo Fisher Scientific, Inc.
Key Segments of the cancer diagnostics market
By Technology, 2015-2025 (USD Billion)
Imaging
Molecular diagnostics
Biopsy
Others
By Application, 2015-2025 (USD Billion)
Breast cancer
Lung cancer
Prostate cancer
Colorectal cancer
Skin cancer
Others
Regional Overview, 2015-2025 (USD Billion)
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Do you have any query or specific requirement? Ask to our industry expert at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/95
About Us
Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a market’s size, key trends, participants and future outlook of an industry. We intend to become our clients’ knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code – Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.
Contact Us:
Ryan Johnson
Account Manager Global
3131 McKinney Ave Ste 600, Dallas,
TX75204, U.S.A.
Phone No.: USA: +1 210-667-2421/ +91 9665341414
